poisar

Stocks · News reference

Evercore ISI Group Maintains Outperform on Charles River, Raises Price Target to $320

Benzinga Newsdesk

Evercore ISI Group analyst Ross Muken maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $300 to $320.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CRL
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Beat the Market the Zacks Way: FIGS, Microsoft, Amphenol in Focus

    Zacks Investment Research showcases the performance of its various stock rating systems and portfolios. The Zacks Rank #1 portfolio outperformed the S&P 500 by 2.3 percentage points year-to-date, while individual stocks like FIGS and CRL surged following rank upgrades. The Focus List, ECAP, ECDP, and Top 10 portfolios also demonstrated strong returns, with the Top 10 portfolio delivering a cumulative return of +2,881.3% since 2012 compared to the S&P 500's +648.5%.

    FIGSCRLAPHCIBMSFT
  2. Bcc Research

    Global Pathology Services Market to Reach $307.9 Billion by 2030, Driven by Rising Cancer Incidence and AI-Enabled Diagnostic Innovation

    The global pathology services market is projected to grow from $212.8 billion in 2024 to $307.9 billion by 2030 at a 6.5% CAGR, driven by rising cancer incidence, digital pathology adoption, and molecular diagnostics expansion. North America leads with 41.2% market share, while AI-enabled platforms are delivering measurable ROI through cost savings and improved efficiency. Large reference laboratory operators are best positioned to capture outsourcing opportunities and scale molecular testing capabilities.

    DGXLHCRLSKHHYERRFY
  3. Zacks.Com

    Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

    RSPH, an equal-weight healthcare ETF launched in 2006, has gained 17.92% year-to-date and 29.15% over the past year as of August 31, 2026. With $826.52 million in assets and a 0.40% expense ratio, it offers diversified exposure to 63 healthcare holdings. However, cheaper alternatives like VHT (0.09% expense ratio) and XLV (0.08% expense ratio) may be more suitable for cost-conscious investors seeking lower-risk options.

    RSPHVHTXLVCRLVEEV